University of South Carolina, Palmetto Health, Pediatrics
Fellowship
University of Alabama at Birmingham, Children's of Alabama, Pediatric Hematology
Notable Publications and Presentations
1. Stafman, L. L., Williams, A. P., Garner, E. F., Aye, J. M., Stewart, J. E., Yoon, K. J., . . . Beierle, E. A. (2018). Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.. Transl Oncol, 12(2), 200-208. doi:10.1016/j.tranon.2018.10.008
2. Williams, A. P., Garner, E. F., Waters, A. M., Stafman, L. L., Aye, J. M., Markert, H., . . . Beierle, E. A. (2018). Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth.. Transl Oncol, 12(1), 84-95. doi:10.1016/j.tranon.2018.09.011
3. Garner, E. F., Stafman, L. L., Williams, A. P., Aye, J. M., Goolsby, C., Atigadda, V. R., . . . Beierle, E. A. (2018). UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.. J Neurooncol. doi:10.1007/s11060-018-2950-1
4. Stafman, L. L., Mruthyunjayappa, S., Waters, A. M., Garner, E. F., Aye, J. M., Stewart, J. E., . . . Beierle, E. A. (2018). Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.. Oncotarget, 9(32), 22665-22679. doi:10.18632/oncotarget.25205
5.Garner, E. F., Williams, A. P., Stafman, L. L., Aye, J. M., Mroczek-Musulman, E., Moore, B. P., . . . Beierle, E. A. (2018). FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.. Sci Rep, 8(1), 6913. doi:10.1038/s41598-018-25263-5
